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ttp://dx.doi.org/10.1016/j.ajpath.2013.10.020Much concern has arisen regarding critical adverse effects of thiazolidinediones (TZDs), including rosi-
glitazone and pioglitazone, on cardiac tissue. Although TZD-induced cardiac hypertrophy (CH) has been
attributed to an increase in plasma volume or a change in cardiac nutrient preference, causative roles have
not been established. To test the hypothesis that volume expansion directly mediates rosiglitazone-
induced CH,mice were fed a high-fat diet with rosiglitazone, and cardiac andmetabolic consequences were
examined. Rosiglitazone treatment induced volume expansion and CH in wild-type and PPARg hetero-
zygous knockout (Ppargþ/) mice, but not in mice defective for ligand binding (PpargP465L/þ). Cotreat-
ment with the diuretic furosemide in wild-type mice attenuated rosiglitazone-induced CH, hypertrophic
gene reprogramming, cardiomyocyte apoptosis, hypertrophy-related signal activation, and left ventricular
dysfunction. Similar changes were observed in mice treated with pioglitazone. The diuretics spi-
ronolactone and trichlormethiazide, but not amiloride, attenuated rosiglitazone effects on volume
expansion and CH. Interestingly, expression of glucose and lipidmetabolism genes in the heart was altered
by rosiglitazone, but these changes were not attenuated by furosemide cotreatment. Importantly,
rosiglitazone-mediated whole-body metabolic improvements were not affected by furosemide cotreat-
ment. We conclude that releasing plasma volume reduces adverse effects of TZD-induced volume expansion
and cardiac events without compromising TZD actions in metabolic switch in the heart and whole-body
insulin sensitivity. (Am J Pathol 2014, 184: 442e453; http://dx.doi.org/10.1016/j.ajpath.2013.10.020)Supported by grants from the Taiwan National Science Council (NSC-
98-2320-B-006-009 and NSC-100-2321-B-006-016 to Y.S.T.), Taiwan
National Health Research Institutes (NHRI-EX102-10231SI to Y.S.T.), and
National Cheng Kung University (NCKU) Aim for the Top University
Project and from the NIH (R01-HL042630 to N.M.).Thiazolidinediones (TZDs), including rosiglitazone and pio-
glitazone, are PPARg agonists successfully used for treat-
ment of diabetes mellitus. However, concerns about cardiac
adverse effects and congestive heart failure due to TZD
treatment have increased in recent years. From a large meta-
analysis, Nissen and Wolski1 reported that rosiglitazone
treatment was associated with increased risks of myocardial
infarction and cardiovascular death; however, subsequent
reports provided a mixed variety of evidence for adverse
cardiovascular effects of rosiglitazone and pioglitazone.2,3
Controversy over TZDs has undermined conﬁdence in
drugs targeting PPARg, and a better understanding of adversestigative Pathology.
.effects is needed to develop safe antidiabetic therapies tar-
geting PPARg.
PPARg activation is known to induce genes involved in
lipid uptake and storage, glucose utilization, and energy
expenditure in adipose tissue. Moreover, PPARg activation
exhibits a variety of systemic effects and, most remarkably,
it directs a greater portion of lipid to adipose tissue.4 In
TZD-Induced Cardiac Hypertrophyaddition to adipose tissue, other tissues, including heart and
kidney, express PPARg at relatively low levels.4 Cardiac
hypertrophy (CH) is accompanied by fetal gene reprogram-
ming, including re-expression of natriuretic peptides and
switches in contractile proteins and metabolic enzymes.5 De-
creases in fatty acid oxidation and increases in glucose utili-
zation lead to a change in preference of nutrient usage from
fatty acids to carbohydrates in the heart. Interferencewith fatty
acid or glucose utilization in rodents has been shown to induce
CH or heart failure, suggesting that alteration in energy sub-
strate is sufﬁcient for induction of CH.5,6 Furthermore,
rosiglitazone-treatedmice show attenuated activation of genes
involved in fatty acid oxidation and lipid uptake in the heart.7
Because gene products downstream of PPARg are critical in
regulation of glucose and lipid metabolism in the heart, it is
reasonable to speculate that PPARg activation induces CH
through modulation of nutrient metabolism.
TZDs may induce CH either directly, acting on the heart, or
indirectly, through effects on noncardiac tissues. For example,
it has been established that rosiglitazone stimulates sodium
reabsorption by increasing renal tubule transporters, including
Atp1a1, NHE3, and Npt2 in the proximal convoluted tubule,
and Nkcc2 in the thick ascending limb.8 Moreover, renal
PPARg activation has been shown to up-regulate ENaCg, a
subunit of sodium transporter in the collecting duct.9,10 Up-
regulation of these renal sodium transporters increases so-
dium reabsorption and further induces volume expansion.
Chronic volume overload is initially compensated for by CH,
but eventually leads to cardiomyopathy and heart failure if the
condition is not resolved.11 However, although TZD-induced
CH has been associated with increases in plasma volume and
changes in nutrient preferences, causative roles have not yet
been established. There has been no direct evidence showing
that a release of plasma volume or blocking of sodium reab-
sorption ameliorates TZD-induced CH.Moreover, efﬁcacy of
diuretics in alleviatingPPARg agonisteinducedhemodilution
in humans remains debatable.12,13
We hypothesized that TZD-induced CH is directly
mediated through volume expansion. To test this hypothesis,
we released TZD-induced volume overload by feeding mice
diuretics [furosemide, amiloride, spironolactone, or tri-
chlormethiazide (TCM)] and then examined PPARg depen-
dence by using PPARg heterozygous knockout (Ppargþ/)
mice and a mutant strain (PpargP465L/þ) that is defective in
the ligand-binding competence of PPARg.14 Our ﬁndings
indicate that simultaneous treatment with furosemide inhibits
CH without affecting TZD-induced metabolic changes in the




The PpargP465L/þ mutation14 was transferred onto a C57BL/
6 genetic background by backcrossing more than 12The American Journal of Pathology - ajp.amjpathol.orggenerations, and PpargP465L/þ and their wild-type (WT)
littermates were used for experiments. Ppargþ/ mice,
provided by Dr. Ronald Evans, were maintained on a 129S6
background and were mated with WT C57BL/6 mice, ob-
tained from the National Laboratory Animal Center (Taipei,
Taiwan), to generate F1 littermates. Male mice at 8 weeks of
age were fed a high-fat diet (58% fat energy) (58R2; Test-
Diet, St. Louis, MO) or a high-fat diet blended with 10 mg/
kg per day rosiglitazone or 40 mg/kg per day pioglitazone
for 4 weeks. In diuretic treatment groups, rosiglitazone-
treated mice were simultaneously treated with diuretics for
4 weeks; 0.1 mg/mL furosemide or 0.02 mg/mL amiloride
was added to drinking water, and 30 mg/kg per day spi-
ronolactone or 15 mg/kg per day TCM was blended with a
high-fat diet supplemented with rosiglitazone. For a furo-
semide withdrawal experiment, furosemide administration
was discontinued after 4 weeks of cotreatment, and rosi-
glitazone treatment was continued for a further 1 or 2 weeks.
Protocols were approved by the Institutional Animal Care
and Use Committees of National Cheng Kung University.
Plasma Volume Analysis
After anesthesia, 0.1 mL of 1 mg/mL Evans Blue dye so-
lution was injected through the portal vein, and after 3
minutes blood was collected from the vena cava. Plasma
volume was calculated as the total amount of injected dye
divided by the concentration of dye in plasma as measured
by spectrophotometer at 620 nm.
Sodium Analysis
For 24-hour urine collection, mice were housed in single-
mouse metabolic cages (Tecniplast, Buguggiate, Italy). Uri-
nary sodium concentrations were measured on day 5 of
treatment using a Dri-Chem 4000i chemistry analyzer (Fuji-
ﬁlm, Tokyo, Japan). Daily sodium excretionwas calculated as
sodium concentration multiplied by urine volume and then
divided by body weight.
Histological Analysis of Heart
Anesthetized mice were perfused with 10% buffered for-
malin. A midventricular slice of myocardium was embedded
in parafﬁn. Sections were cut, stained with H&E, and
analyzed using ImageJ software version 1.42q (NIH,
Bethesda,MD). For examining apoptosis, parafﬁn sections of
heart were analyzed by TUNEL assay (Clontech Labora-
tories, Mountain View, CA). For immunohistochemical
staining, sections were deparafﬁnized, blocked, and incu-
bated overnight with primary antibodies against p-Erk1/2
(Cell Signaling Technology, Danvers, MA). Secondary
antibody staining was performed using a kit (Vector Labo-
ratories, Burlingame, CA), and detection was performed
using a 3,30-diaminobenzidine substrate chromogen solution
(Dako, Carpinteria, CA).443
Chang et alRNA Analysis
Tissues were stored in Ambion RNAlater stabilization so-
lution (Life Technologies, Carlsbad, CA), and total RNA
was extracted with REzol isolation reagent (Protech Tech-
nology Enterprise, Taipei, Taiwan). Samples of mRNA
were analyzed with SYBR Greenebased real-time quanti-
tative reverse transcription PCR (RT-qPCR), with Gapdh as
the reference gene in each reaction.
Echocardiography
Isoﬂurane-anesthetized mice were placed on a heating pad
in a supine position. Echocardiographic images were ob-
tained using a Vevo 770 microimaging system with a
25-MHz probe (VisualSonics, Toronto, ON, Canada). Par-
asternal short-axis views of left ventricle (LV) were ac-
quired at the papillary muscle level, and M-mode records
were obtained.
Western Blotting
Total protein (20 mg) from the lower portion of hearts was
separated by SDS-PAGE, transferred to polyvinylidene
diﬂuoride membranes (Pall Gelman Laboratory, Ann Arbor,
MI), and probed with antibodies. Immunoreactive proteins
were detected using an enhanced chemiluminescence
Western blotting detection system (GE Healthcare, Little
Chalfont, UK).
Statistical Analysis
Statistical analyses were performed using Student’s t-test or
one-way analysis of variance followed by Fisher’s least
signiﬁcant difference (LSD) multiple comparison test. Dif-
ferences were considered statistically signiﬁcant at P <
0.05. Data are expressed as means  SEM.Figure 1 Volume expansion and CH in the hearts of rosiglitazone-treated mice
PpargP465L/þ (defective for ligand binding). AeC: Hematocrit (A), HW (B), and HW/B
genes, relative to average expression in Ppargþ/þ mice without rosiglitazone trea
(indicated on data bars). *P < 0.05, **P < 0.01, and ***P < 0.001, Student’s t-
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Rosiglitazone Induces Volume Expansion and CH
through PPARg
To induce insulin resistance, all experimental mice were fed
a high-fat diet for 4 weeks with or without rosiglitazone.
The rosiglitazone-supplemented diet induced hemodilution,
reﬂected by decreased hematocrit, and an increase in heart
weight (HW) in WT mice in a dose-dependent manner
(Supplemental Figure S1). Because treatment with rosigli-
tazone at 10 mg/kg per day for 4 weeks induced a signiﬁcant
increase in the heart weight/body weight ratio (HW/BW),
compared with those on a control diet without rosiglitazone
supplement, we chose this dosage for experiments. The
same rosiglitazone-supplemented regular chow also induced
hemodilution and CH in WT mice (data not shown).
To investigate whether the effects of rosiglitazone on
hemodilution and CH are dependent on PPARg, Ppargþ/
and PpargP465L/þ mice were used. Basic cardiac phenotypes
of Ppargþ/ and PpargP465L/þ mice appear normal.14e16
Hematocrit and HW of Ppargþ/ mice on the control diet
did not differ different from those of WT mice. Furthermore,
rosiglitazone treatment decreased hematocrit and increased
HW in both WT and Ppargþ/ mice, and to similar extent
(Figure 1, AeC). These ﬁndings indicate that rosiglitazone
can nevertheless cause volume expansion and CH, despite a
50% reduction in PPARg expression.
The P465L mutation in the ligand-binding domain of
PPARg suppresses PPARg activation in a dominant-
negative fashion.14 Nevertheless, basal hematocrit and HW
of the heterozygous PpargP465L/þ mice did not differ from
those of WT mice. Interestingly, however, the effect of
rosiglitazone on hemodilution was blunted in PpargP465L/þ
mice (Figure 1A). Consistent with the absence of volume
expansion, rosiglitazone treatment did not induce an increase
in HW in PpargP465L/þ mice (Figure 1, B and C).of three genotypes: Ppargþ/þ (WT), Ppargþ/ (heterozygous knockout), and
W ratio (C). DeF: mRNA levels of hypertrophic (D) and metabolism (E and F)
tment. Data are expressed as means  SEM. n Z 6 to 15 mice per group
test. Con, control (black bars); Rosi, rosiglitazone (white bars).
ajp.amjpathol.org - The American Journal of Pathology
TZD-Induced Cardiac HypertrophyNo differences were found in basal expression of natri-
uretic peptide or in glucose and lipid metabolism among
WT, Ppargþ/, and PpargP465L/þ mice. However, although
both WT and Ppargþ/ mice responded to rosiglitazone
similarly, with altered expression of genes for natriuretic
peptide [natriuretic peptide type B (Nppb)] and metabolism
[pyruvate dehydrogenase kinase isoenzyme 4 (Pdk4) and
acyl-coenzyme A dehydrogenase, medium chain (Acadm)],
expression of these genes was not affected in rosiglitazone-
treated PpargP465L/þ mice (Figure 1, DeF).
Taken together, these ﬁndings demonstrate that
rosiglitazone-induced volume expansion and CH, as well as
dysregulation in hypertrophic and metabolism genes, all
require intact ligand-binding ability of PPARg. In contrast,
a 50% normal level of PPARg expression is sufﬁcient to
mediate dysregulation of both hypertrophic and metabolism
gene expression in the heart.
Cotreatment with Furosemide Prevents Rosiglitazone-
Induced Volume Expansion and CH
To determine whether volume expansion is causative of
rosiglitazone-induced HW gain, we next fed WT mice a dietFigure 2 Effects of furosemide on rosiglitazone-induced volume expansion and C
(A), the ratio of plasma volume to BW (B), hematocrit (C), HW (D), and HW/BW ratio
mice. F: Correlation between HW/BW ratio and hematocrit in control (squares),
(crosses). nZ 27 mice per group. G and H: Hematocrit (G) and HW (H) in the furose
for 1 week after discontinuing furosemide cotreatment (S1W). I: Gross appearance
mouse hearts. Data are expressed as means  SEM. n Z 5, 10, 11, or 27 mice per
***P < 0.001, Fisher’s LSD test. Furo, furosemide.
The American Journal of Pathology - ajp.amjpathol.orgsupplemented with both rosiglitazone and furosemide, to
release volume expansion. Treatment with rosiglitazone for 5
days signiﬁcantly lowered urinary sodium excretion, which is
inhibited by furosemide cotreatment (Figure 2A).After 4weeks
of cotreatment, furosemide prevented increases in plasma vol-
ume and HW (Figure 2, BeE). These ﬁndings directly indicate
that releasing volume expansion is protective against increases
in HW caused by rosiglitazone treatment. Furthermore, we
found a strong inverse correlation between HW/BW ratio and
hematocrit (r Z 0.4205; P < 0.0001) (Figure 2F). This
observation further supports causality between volume expan-
sion and HW gain. Finally, we investigated the durability of
furosemide effect and found that volume expansion and CH
reappeared after discontinuing furosemide administration for
1 week (Figure 2, G and H, and Supplemental Figure S2).
No notable change in ventricular ﬁbrosis was found in
rosiglitazone-treated hearts (data not shown). Gross exami-
nation showed that both long and short axes of the heart
were increased by rosiglitazone treatment, and that these
increases were blunted by cotreatment with furosemide
(Figure 2I and Supplemental Figure S3). Morphometric
analyses of the dissected heart did not reveal any differences
in LV wall thickness among the three groups; however, LVH. AeE: Daily sodium excretion expressed as the ratio of urinary sodium to BW
(E) of control, rosiglitazone-treated, and rosiglitazoneþfurosemideetreated
rosiglitazone-treated (circles), and rosiglitazoneþfurosemideetreated mice
mide withdrawal experiment. Mice were continually treated with rosiglitazone
(top row), cross section (middle row), and tissue section (bottom row) of
group, as indicated on data bars (AeE, G, H). *P < 0.05, **P < 0.01, and
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Figure 3 Gene expression and signaling path-
ways in rosiglitazone-induced CH. AeC: Expression
of contractile and natriuretic peptide genes (A),
Myh7/Myh6 ratio (B), and the number of TUNEL-
positive cells (C) in whole sections of hearts of
control, rosiglitazone-treated, and rosiglitazoneþ
furosemideetreated mice. mRNA levels are ex-
pressed relative to average expression in control
mice. D: Immunoblot analyses of phosphorylation
of FAK, Erk1/2, p38, JNK, Akt, and GSK3a/b in the
heart. Each band represents tissue extract from a
single mouse; arrows indicate different molecular
weights of the protein isoforms. E: Immunohisto-
chemical staining of p-Erk1/2 (brown) in the heart.
In each image, a cell marked by an arrow is shown
at higher magniﬁcation in the inset. Data are
expressed as means  SEM. nZ 6 mice per group.
*P < 0.05, **P < 0.01, and ***P < 0.001, Fisher’s
LSD test. Scale barZ 50 mm.
Chang et alchamber size appeared larger in the rosiglitazone treatment
group, and this was inhibited by furosemide cotreatment.
Light microscopic examination revealed no differences in
cardiomyocyte diameters or nucleus size among the three
groups.
CH and stressed heart are known to be associated with
fetal gene reprogramming and cardiomyocyte apoptosis.5
Rosiglitazone treatment tended to decrease mRNA levels
of myosin heavy polypeptide 6 (Myh6) and signiﬁcantly
increased mRNA levels of myosin heavy polypeptide 7
(Myh7) (Figure 3A), resulting in a signiﬁcant increase in
Myh7/Myh6 ratio (Figure 3B). Rosiglitazone treatment also
signiﬁcantly increased mRNA levels of skeletal muscle
actin a1 (Acta1), natriuretic peptide type A (Nppa), and
Nppb. Cotreatment with furosemide did not increase
mRNA levels of Myh7, Acta1, Nppa, or Nppb, nor did it
alter Myh7/Myh6 ratio or decrease mRNA levels of Myh6.
Furthermore, the number of apoptotic cells, as indicated by446TUNEL staining, was signiﬁcantly increased in the hearts of
rosiglitazone-treated mice but was unchanged in the hearts
of rosiglitazoneþfurosemideetreated mice (Figure 3C).
Next, we evaluated cardiac function by echocardiography
(Table 1). Rosiglitazone treatment alone signiﬁcantly
increased systolic and diastolic LV chamber size, whereas
furosemide cotreatment attenuated systolic chamber size
and tended to decrease diastolic chamber size. No notable
changes were found in stroke volume and cardiac output;
however, fractional shortening and ejection fraction were
signiﬁcantly decreased by rosiglitazone treatment, and these
changes were blunted by furosemide cotreatment. These
ﬁndings indicate that rosiglitazone-impaired cardiac func-
tion can be inhibited by furosemide-mediated release of
volume overload. Taken together, the fetal gene reprog-
ramming, apoptosis of cardiomyocytes, and functional
changes are consistent with our hypothesis that rosiglitazone
treatment causes CH and that this CH is prevented byajp.amjpathol.org - The American Journal of Pathology
Table 1 Echocardiographic Measurements
Measure Control Rosiglitazone Rosiglitazone þ furosemide
Sample size n Z 5 n Z 5 n Z 6
LVDd (mm) 4.14  0.09 4.76  0.14** 4.58  0.11*
LVDs (mm) 2.72  0.08 3.63  0.13*** 3.29  0.09**y
LVEVd (mL) 0.076  0.004 0.107  0.007** 0.097  0.006*
LVEVs (mL) 0.028  0.002 0.056  0.005*** 0.044  0.003**y
Stroke volume (mL) 0.048  0.002 0.050  0.002 0.053  0.003
Cardiac output (mL/min) 16.9  0.9 17.3  1.0 16.9  1.4
FS (%) 34.36  0.74 23.85  0.62*** 28.31  0.83***yy
EF (%) 63.71  1.04 47.5  1.12*** 54.67  1.26***yy
*P < 0.05, **P < 0.01, and ***P < 0.001 versus control, Fisher’s LSD test.
yP < 0.05, yyP < 0.001 versus rosiglitazone, Fisher’s LSD test.
EF, ejection fraction; FS, fractional shortening; LVDd, left ventricular diastolic diameter; LVDs, left ventricular systolic diameter; LVEVd, left ventricular end-
diastolic volume; LVEVs, left ventricular end-systolic volume.
TZD-Induced Cardiac Hypertrophyreleasing volume expansion, despite continued treatment
with rosiglitazone.
Rosiglitazone-Induced CH Is Mediated through Erk1/2
Signaling
Because focal adhesion kinase (FAK) and mitogen-activated
protein kinases (MAPKs) are important mediators of
CH,17,18 we analyzed signaling pathways in relation to
volume expansion and CH. Rosiglitazone treatment induced
phosphorylation of FAK and Erk1/2, and furosemide
cotreatment inhibited these effects (Figure 3D). In contrast,
phosphorylation of p38, JNK, Akt, and GSK3a/b was
not affected by rosiglitazone or rosiglitazoneþfurosemide
treatment. Immunohistochemical analysis conﬁrmed nuclear
localization of p-Erk1/2 in cardiomyocytes of rosiglitazone-
treated mice; nuclear localization was absent in cells of mice
cotreated with furosemide (Figure 3E). These ﬁndings
suggest that Erk1/2 is a volume expansionedependent
signal leading to rosiglitazone-induced CH.
Pioglitazone-Induced CH Is Also Mediated through
Volume Expansion
Although a retrospective cohort study showed relatively lesser
cardiac risk with pioglitazone than with rosiglitazone,19 in-
duction of CH by pioglitazone has been reported.20 In the
present study, feedingmicewith a diet containing pioglitazone
for 4 weeks reduced hematocrit and increased HW in a dose-
dependent fashion (Supplemental Figure S4). Pioglitazone at
a dose of 40 mg/kg per day induced cardiac effects similar to
those induced by rosiglitazone at 10 mg/kg per day. Cotreat-
ment with furosemide protected mice from pioglitazone-
mediated decrease in hematocrit and increase in heart mass
(Figure 4, AeC), and therewas an inverse correlation between
HW/BW ratio and hematocrit (r Z 0.5170; P Z 0.0012)
(Figure 4D). Consistently, pioglitazone treatment induced
reprogramming of hypertrophic genes and increased phos-
phorylation of FAK and Erk1/2, and cotreatment withThe American Journal of Pathology - ajp.amjpathol.orgfurosemide ameliorated these changes (Figure 4, EeG). These
ﬁndings indicate that, as for rosiglitazone, volume expansion
is an important factor causing CH in response to pioglitazone
treatment. Overall effects of pioglitazone and rosiglitazone on
the heart are summarized in Supplemental Table S1.
Spironolactone and TCM Prevent
Rosiglitazone-Induced Volume Expansion and CH
Rosiglitazone treatment signiﬁcantly increased mRNA
levels of ENaCa, ENaCb, and ENaCg (Scnn1a, Scnn1b,
and Scnn1g, respectively), and protein levels of ENaCg in
the kidney (Figure 5, A and B). In addition, rosiglitazone
treatment signiﬁcantly increased mRNA levels of Npt2
(Slc34a1), Atp1a1, and Nkcc2 (Slc12a1), but not NHE3
(Slc9a3) or NCC (Slc12a3). These ﬁndings suggest that
renal transporters other than ENaC may be involved in
rosiglitazone-induced water reabsorption; this could explain
the effective protection by furosemide, which blocks Nkcc2.
Next, we tested the effects of other diuretic agents.
Cotreatment with amiloride, a speciﬁc ENaC blocker, did
not signiﬁcantly attenuate the decrease of urinary sodium
excretion (Supplemental Figure S5). Consequently,
rosiglitazone-induced plasma volume expansion and CH
were not inhibited by amiloride. In contrast, cotreatment with
either spironolactone (an aldosterone receptor blocker which
indirectly inactivates ENaC) or TCM (a speciﬁc NCC
blocker) inhibited the rosiglitazone-induced decrease of uri-
nary sodium excretion and modulated rosiglitazone effects
on plasma volume expansion and CH (Figure 5, CeF).
Glucose and Lipid Metabolism Genes Are Not
Dependent on Volume Expansion in TZD-Induced CH
Because PPARg is important in regulation of nutrient utiliza-
tion, we next investigated whether genes related to glucose and
lipid metabolism are involved in rosiglitazone-mediated CH.
mRNA levels of glucose transporter Glut1 (Slc2a1) and Glut4
(Slc2a4), glycolysis (hexokinase 2;Hk2), and glycogenosis and447
Figure 4 Effects of furosemide on pioglitazone-induced volume expansion and CH. AeC: Hematocrit (A), HW (B), and HW/BW ratio (C) of control,
pioglitazone-treated, and pioglitazoneþfurosemideetreated mice. D: Correlation between HW/BW ratio and hematocrit in control (squares), pioglitazone-
treated (circles), and pioglitazoneþfurosemideetreated mice (crosses). n Z 12 mice per group. E and F: Expression of contractile and natriuretic peptide
genes (E) and the Myh7/Myh6 ratio (F). mRNA levels are expressed relative to average expression in control mice. G: Immunoblot analyses of phosphorylation
of FAK and Erk1/2 in the heart. Bands and arrows are as described for Figure 3. Data are expressed as means  SEM. nZ 12 mice per group. *P < 0.05, **P <
0.01, and ***P < 0.001, Fisher’s LSD test. Pio, pioglitazone.
Chang et alglycogenolysis were not affected by rosiglitazone or rosiglita-
zoneþfurosemide (Supplemental FigureS6).However,mRNA
levels of Pdk4, which inhibits glucose utilization by reducing
conversion of pyruvate into acetyl-CoA, were dramatically
down-regulated by rosiglitazone (Figure 6A). Importantly,
normalization of CH by cotreatment with furosemide did not
inhibit rosiglitazone-induced Pdk4 down-regulation.
Among the molecules involved in cellular fatty acid
transport, mRNA levels of lipoprotein lipase (Lpl) were
not affected by rosiglitazone or rosiglitazoneþfurosemide
(Supplemental Figure S6). Although fatty acid translocase
(Cd36) was up-regulated, fatty acid transporter member 1
(FATP1; Slc27a1) was down-regulated in both groups
(Figure 6B). Surprisingly, genes involved in mitochondrial
fatty acid oxidation [carnitine palmitoyltransferase 1b and 2
(Cpt1b and Cpt2); acyl-coenzyme A dehydrogenase, long
chain (Acadl); Acadm; and mitochondrial uncoupling
protein 3 (Ucp3)] were signiﬁcantly down-regulated by
rosiglitazone treatment (Figure 6C). Cotreatment with
furosemide did not attenuate rosiglitazone-induced down-
regulation of these genes. Moreover, the down-regulation of
fatty acid oxidation appears to be speciﬁc to mitochondria,
because mRNA levels of peroxisomal acyl-coenzyme A448oxidase 1 (Acox1) was not affected by either rosiglitazone or
rosiglitazoneþfurosemide (Supplemental Figure S6). These
ﬁndings suggest that rosiglitazone-induced CH is associated
with down-regulation of mitochondrial fatty acid oxidation,
but that amelioration of plasma overload and CH does not
affect the down-regulated mitochondrial fatty acid oxida-
tion. These ﬁndings further suggest that rosiglitazone
treatment shifts metabolism genes toward glucose-usage
preference, independent of volume expansion. Similarly,
pioglitazone treatment also shifted metabolism genes toward
glucose-usage preference, and cotreatment with furosemide
did not attenuate these changes (Supplemental Figure S7).
Consistent with the metabolism gene expression pattern,
rosiglitazone treatment signiﬁcantly decreased heart tri-
glyceride content, and furosemide cotreatment did not
attenuate this change (Figure 6D).
Furosemide Cotreatment Does Not Compromise
Whole-Body Insulin-Sensitizing Effects of TZD
Finally, we investigated whether furosemide cotreatment af-
fects the insulin-sensitizing activity of rosiglitazone. Mice fed
the control high-fat diet for 4 weeks exhibited compromisedajp.amjpathol.org - The American Journal of Pathology
Figure 5 Effects of spironolactone and TCM on rosiglitazone-induced volume expansion and CH. A: Expression of sodium transporter genes in renal tubule
in the kidneys of control and rosiglitazone-treated mice. mRNA levels are expressed relative to average expression in control mice. B: Immunoblot analyses of
ENaCg in the kidney. Each band represents a single mouse; both 85- and 70-kDa bands represent ENaCg. CeF: Daily sodium excretion (C), plasma volume (D),
HW (E), and HW/BW ratio (F) of control, rosiglitazone-treated, rosiglitazoneþspironolactone-treated, and rosiglitazoneþTCM-treated mice. Data are expressed
as means  SEM. n Z 6 (A) or 11e14 (CeF) mice per group (indicated on data bars). *P < 0.05, **P < 0.01, and ***P < 0.001, Student’s t-test (A) or
Fisher’s LSD test (CeF). Spiro, spironolactone.
TZD-Induced Cardiac Hypertrophymetabolic parameters (Table 2). Supplementing this high-fat
diet with rosiglitazone effectively attenuated many of the
metabolic parameters, although total BW and gonadal fat
mass were not altered. In contrast, rosiglitazone treatment
caused a signiﬁcant increase in inguinal fat mass, suggesting
that a greater portion of lipids are channeled to subcutaneous
adipose tissue by PPARg activation. This resulted in reduc-
tion of the intraperitoneal/subcutaneous fat mass ratio; a lower
ratio is generally considered to reﬂect a preferable distribution
of body fat. Rosiglitazone treatment attenuated impairments
of glucose metabolism, as evidenced by lower levels of
plasma insulin, fatty acids, and glucose, as well as lower
homeostatic model assessment (HOMA) index and higher
plasma adiponectin levels, relative to control treatment.
Importantly, metabolic parameters in mice cotreated with
rosiglitazone and furosemide did not differ from those in
mice treated with rosiglitazone alone, except that mice in the
cotreatment group consumed more water, indicative of thirst
resulting from diuresis. These ﬁndings demonstrate that
release of volume overload does not compromise either theThe American Journal of Pathology - ajp.amjpathol.orginsulin-sensitizing effects of TZD or the improvement of
glucose homeostasis.
Discussion
With the present study, we have demonstrated that
rosiglitazone-induced CH in mice is mediated through
PPARg activation and requires intact ligand-binding ability of
PPARg. We further demonstrated that releasing volume
overload attenuates rosiglitazone-induced CH, hypertrophic
gene reprogramming, cardiomyocyte apoptosis, hypertrophy-
related signal activation, and LV dysfunction. These
effects are therefore attributable to volume expansion and
are unlikely to be direct effects of rosiglitazone in the heart.
In contrast, expression of glucose and lipid metabolism
genes in the heart was altered by rosiglitazone, but these
changes were not attenuated by release of volume overload,
suggesting that regulation of nutrient metabolism genes is
independent of volume expansion but dependent on pres-
ence of rosiglitazone.449
Figure 6 Expression of glucose and lipid metabolism genes in rosiglitazone-induced CH. Expression of genes for glucose utilization (A), lipid transport (B),
and fatty acid oxidation (C) and triglyceride contents (D) in the hearts of control, rosiglitazone-treated, and rosiglitazoneþfurosemideetreated mice. mRNA
levels are expressed relative to average expression in control mice. Data are expressed as means  SEM. nZ 12 mice per group. *P < 0.05, **P < 0.01, and
***P < 0.001, Fisher’s LSD test. TG, triglyceride.
Chang et alOne approach to addressing PPARg dependence of TZD-
induced CH would be the use of PPARg-deﬁcient mice. In
the present study, rosiglitazone-induced volume expansion
and CH were attenuated in PpargP465L/þ mice, but not in
Ppargþ/ mice. Although the genetic backgrounds of the
PpargP465L/þ and Ppargþ/ mice described here are
different, the effect of rosiglitazone on CH was also blunted
in PpargP465L/þ mice on a 129S6:C57BL/6 F1 background
(data not shown). This indicates that 50% normal expression
of PPARg is sufﬁcient to mediate rosiglitazone-induced CH,
but that the dominant-negative effect of ligand-binding




BW (g) 27.6  0.8 30.
Gonadal weight/BW (mg/g) 10.4  1.0 23.
HW/Body length (mg/cm) 13.3  0.5 13.
Inguinal weight/BW (mg/g) 6.9  0.5 11.
Gonadal weight/inguinal weight (mg/mg) 1.51  0.09 1.9
Insulin (ng/mL) 0.14  0.05 3.1
Glucose (mg/dL) 134  14 25
HOMA index 1.2  0.5 52.
Free fatty acid (mEq/L) 0.40  0.04 0.7
Adiponectin (mg/mL) ND 5.
Mean blood pressure (mmHg) ND 9
Water consumption (mL/day per mouse) ND 4.
Food consumption (g/day per mouse) ND 2.3
The data for the regular chow group (nZ 3 to 12) were obtained in separate exp
included in the statistical analyses. For high-fat diet experiments, n Z 5 mice pe
HOMA index, and adiponectin; n Z 10 or 11 for food consumption; and n Z 27
*P < 0.05, **P < 0.01, and ***P < 0.001 versus control, Fisher’s LSD test.
yP < 0.001 versus rosiglitazone, Fisher’s LSD test.
ND, not determined.
450It has been suggested that both cardiac and noncardiac
PPARg activity contribute to TZD-induced CH. In a study by
Duan et al,21 rosiglitazone treatment of cardiac-speciﬁc
PPARg knockout mice with 10 mg/kg per day for 4 weeks
caused CH, but to a lesser extent than in rosiglitazone-treated
WT mice. In terms of the role of PPARg in noncardiac
tissues, two studies demonstrated that renal PPARg activa-
tion by TZDs up-regulates ENaCg and increases water
reabsorption.9,10 Although TZD-induced hemodilution
occurred only in the presence of intact collecting-duct
PPARg, those studies did not address effects of collecting-
duct PPARg on TZD-induced CH. In the present study, theh-fat diet
trol Rosiglitazone Rosiglitazone þ furosemide
3  0.7 31.2  0.6 29.9  0.5
8  2.1 23.3  1.1 21.3  1.6
5  0.3 15.6  0.4*** 13.6  0.3y
9  0.7 18.2  0.9*** 15.7  1.1**
5  0.07 1.29  0.03*** 1.35  0.03***
2  0.71 0.74  0.16** 1.14  0.44*
7  20 201  9* 173  13***
3  16.0 9.3  2.4** 13.5  6.6*
7  0.11 0.35  0.03*** 0.42  0.03**
2  0.4 13.0  0.4*** 12.2  0.7***
8  1 89  2** 92  1*
8  0.4 4.2  0.2 11  0.4***y
6  0.13 2.49  0.15 2.50  0.07
eriments from those for the experimental high-fat diet groups and were not
r group for free fatty acid and blood pressure; n Z 6 for insulin, glucose,
for all other measurements.
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TZD-Induced Cardiac Hypertrophyextent of CH was strongly correlated with the extent of vol-
ume expansion. Furthermore, effective reduction of hyper-
trophy by release of plasma volume with diuretics conﬁrms
the dependence of TZD-induced CH on volume expansion
due to PPARg activation in noncardiac tissues. Diuretic
agents typically decrease blood pressure in addition to
reducing blood volume, which may contribute to reduced CH
and dysfunction. Rosiglitazone decreased mean blood pres-
sure, and that furosemide cotreatment did not cause further
changes in blood pressure (Table 2). These ﬁndings suggest
that the inhibition of CH by furosemide cotreatment is not
likely attributable to change in blood pressure.
Mechanical stretch triggers FAK phosphorylation, fol-
lowed by recruitment of Erk1/2 to FAK and activation of
Erk1/2 during increased myocardial workload.18 Erk1/2
activation regulates expression of structural and hypertrophy-
responsive genes through phosphorylation and activation of
transcription factors, such as Gata4 and Elk1.22 Our ﬁndings
suggest that volume expansion by TZD treatment increases
mechanical stretch and so triggers FAK and Erk1/2 activa-
tion. Impeding volume expansion prevents FAK and Erk1/2
activation, and so prevents subsequent dysregulation of
hypertrophy-responsive genes. Thus, FAK and Erk1/2 acti-
vation is critical in TZD-induced volume overload and CH.
How does volume expansion lead to cardiac dysfunction
during rosiglitazone treatment? Volume overload increases
stretching force on the myocardium and leads to myocardial
apoptosis. Apoptosis of cardiomyocytes then reduces the
contractile force, contributing to progressive LV dysfunc-
tion.23,24 In the present study, rosiglitazone-induced volume
expansion was associated with increased myocardial
apoptosis and LV dysfunction. Release of volume expan-
sion ameliorated both apoptosis and LV dysfunction,
implicating a volume expansioneapoptosiseLV dysfunc-
tion axis in rosiglitazone-induced CH.
Although our ﬁndings of a signiﬁcant increase in expres-
sion of three subunits of ENaC are compatible with the notion
that rosiglitazone-induced ﬂuid retention is mediated by
activation of ENaC, recent studies argue against ENaC in
TZD-mediated ﬂuid retention. For example, several research
groups found no change or even decreases in expression of
ENaC subunit in rodents or in cultured cells treated with
TZDs.25,26 Functional inactivation of ENaCa did not protect
animals against rosiglitazone-induced ﬂuid retention.27
Furthermore, and in contrast, chronic rosiglitazone treat-
ment improved renal handling of salt and water in rats with
pre-existing heart failure.28 Efﬁcacy of amiloride in allevi-
ating PPARg agonist-induced ﬂuid retention also remains
debatable.29 In the present study, cotreatment with amiloride
did not prevent rosiglitazone-induced volume expansion and
CH. Treatment with a higher dose of amiloride (0.1 mg/mL in
drinking water) affected appetite and caused BW loss (data
not shown). These ﬁndings argue against stimulation of
ENaC as the initial target of PPARg agonist-mediated ﬂuid
retention and suggest involvement of renal transporters other
than ENaC in rosiglitazone-induced water reabsorption.The American Journal of Pathology - ajp.amjpathol.orgShort-term (3-day) treatment with rosiglitazone increases
protein levels of Atp1a1, Npt2, and NHE3 in the proximal
convoluted tubule and of Nkcc2 in the thick ascending
limb.8 In accord, our results with a relatively long-term
rosiglitazone treatment (4 weeks) also demonstrated up-
regulation of mRNA levels of Atp1a1, Npt2, and Nkcc2.
Although mRNA or protein abundance does not always
reﬂect membrane-bound transporter activity, further atten-
tion should be focused on ENaCg and other sodium trans-
porters of renal tubule in rosiglitazone-induced sodium
reabsorption. One clinical trial with an acute diuretic treat-
ment (7 days) showed that rosiglitazone-induced hemodi-
lution was reversed by treatment with spironolactone or
thiazides (hydrochlorothiazide), but not with furosemide.12
Another clinical trial, however, showed preserved re-
sponse to furosemide in rosiglitazone-treated insulin-resis-
tant subjects.13 In our rodent model with 4-week diuretic
treatment, furosemide attenuated rosiglitazone-induced
volume expansion and CH to an extent similar to that
observed with spironolactone or TCM. Spironolactone is
known to block aldosterone receptoremediated sodium
reabsorption. Thus, in addition to ENaC, other transporters
(including NHE3, NCC, and Atp1a1) are affected by spi-
ronolactone.30 This may explain why spironolactone is
more effective than amiloride in release of rosiglitazone-
mediated dysregulation in sodium balance and volume
handling. On the other hand, although our ﬁndings did not
suggest a role of NCC in rosiglitazone-induced ﬂuid
retention (as indicated by unchanged NCC expression in
rosiglitazone treatment), forced inhibition of NCC by TCM
effectively protected mice against rosiglitazone-induced
volume expansion and CH. Thus, therapy against TZD-
induced volume expansion is not necessarily limited to
targeting the speciﬁc transporters whose expression is
affected during TZD treatment.
The mechanism of TZDs in increasing insulin sensitivity
is redirection of lipid to adipose tissues, which is orches-
trated by adipose PPARg in coordination with nonadipose
PPARg. Thus, the in vivo effects of TZDs on the heart are
complicated by changes in plasma and tissue lipid meta-
bolism. The present study, together with those of others,7,31
clearly demonstrates a paradoxical reduction in cardiac
expression of many PPARg downstream genes, including
those for lipid transport and fatty acid oxidation. Similarly,
we also found that rosiglitazone treatment led to a change in
nutrient-usage preference from fatty acids to carbohydrates
in the heart. This is coordinated by down-regulation of
genes for glycolysis inhibition (Pdk4) and mitochondrial
fatty acid oxidation in the heart. Redirection of lipid to
adipose tissue is also evidenced by reduction of heart tri-
glyceride content and increase in subcutaneous inguinal fat
weight. Importantly, the shift of energy preference to
glucose in the heart and the redirection of lipid to adipose
tissue are not inhibited by release of volume overload,
despite reversal of increase in heart mass, suggesting that
these actions of TZDs are not likely to be the major cause of451
Chang et alCH. In addition, the effect of furosemide is relatively brief;
in the present study, volume expansion and CH reappeared
after discontinuing furosemide administration for 1 week.
Thus, coprescription of diuretics and hematocrit monitoring
are advised for patients being treated with TZDs.
In our study, furosemide cotreatment did not affect
insulin-sensitizing activity of rosiglitazone, even though
some values in the cotreatment group showed a slight
attenuation (Table 2). It is likely that the parameters in blood
are affected by plasma volume, because furosemide has
been reported to increase lipid levels by changing the
intravascular volume.32 In summary, our results provide
direct evidence that cotreatment with diuretics can reduce
adverse effects of TZD-induced volume expansion and
cardiac events without compromising the action of TZD on
glucose usage in the heart and without compromising
whole-body insulin sensitivity. This cotreatment strategy
could be adopted immediately, without withdrawal of TZDs
and testing new drugs that target PPARg.
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